A study investigating specific electrophenotypes in Atrial Fibrillation was terminated on 2026-03-12 after enrolling only 1 participant.

Background

Atrial fibrillation (AF) is a common heart rhythm disturbance, or arrhythmia, that can significantly impact patient quality of life and health outcomes. Current treatment approaches include direct current cardioversion (DCCV), a procedure designed to revert the heart to a normal rhythm. However, for many patients, the benefit of DCCV is transient, with the heart often returning to AF. Ablation is a more invasive procedure that creates scar tissue within the heart to reduce arrhythmias, offering a potentially longer-lasting effect than DCCV. Ablation has shown success in AF that occurs occasionally. This study aimed to improve understanding of how best to treat AF in different patients by investigating specific electrophenotypes.

Trial design

This study, designated as Phase NA, was terminated with an enrollment of 1 participant. The trial was designed to investigate conditions including Atrial Fibrillation. The study's objective was to investigate specific electrophenotypes in atrial fibrillation to improve understanding of treatment approaches. No specific interventions were listed for this study.

What this means

The termination of this study with only 1 participant enrolled indicates that no meaningful data or conclusions regarding specific electrophenotypes in Atrial Fibrillation could be drawn from its conduct. The early termination and minimal enrollment suggest that the study did not progress to a stage where it could contribute to the understanding of AF treatment strategies as initially intended. Therefore, this event does not provide new clinical insights for patients with atrial fibrillation or for clinicians managing the condition.

Source

The information regarding this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT05366530, titled "Specific Electrophenotypes in Atrial Fibrillation", were posted on 2026-03-12 on clinicaltrials.gov.